[1] Han BF, Zheng RS, Zeng HM, et al.Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53.
[2] 中华人民共和国国家卫生健康委员会等. "原发性肺癌诊疗指南(2022年版)." 中国合理用药探索 19.9(2022):28.
[3] Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol. 2020;13(1):143. Published 2020 Oct 27.
[4] 中国医疗保健国际交流促进会肿瘤内科学分会,中国医师协会肿瘤医师分会.Ⅳ期原发性肺癌中国治疗指南(2024版)[J].中华肿瘤杂志, 2024, 46(07):595-636.
[5] 中国心血管病风险评估和管理指南编写联合委员会.中国心血管病风险评估和管理指南[J].中国循环杂志. 2019.34(1):4-28.
[6] Naranjo CA, Busto U, Sellers EM, et al.A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther. 1981;30(2):239-245.
[7] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)肿瘤心脏病学指南2023[M]. 北京: 人民卫生出版社, 2023.
[8] Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). JACC CardioOncol. 2019;1(2):172-178. Published 2019 Dec 17.
[9] 曹莹,俞森权,郑健,等.贝伐珠单抗联合奥希替尼治疗晚期肺腺癌致心力衰竭1例[J].中国肿瘤临床, 2020, 47(3):2.DOI:CNKI:SUN:ZGZL.0.2020-03-014.
[10] Shinomiya S, Kaira K, Yamaguchi O, Ishikawa K, Kagamu H. Osimertinib induced cardiomyopathy: A case report. Medicine (Baltimore). 2020 Sep 25;99(39):e22301.
[11] 唐倩雯,徐倩.甲磺酸奥希替尼片治疗晚期肺腺癌致急性充血性心力衰竭1例[J].药物流行病学杂志, 2021, 30(11):3.
[12] Bardaro F, Stirpe E.Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.J Oncol Pharm Pract. 2022;28(4):989-994.
[13] 李国银,林淑媛,卞丽,等.奥希替尼致晚期肺腺癌患者心肌损伤1例[J].药物流行病学杂志, 2023, 32(2):233-236.
[14] Bak M, Park H, Lee SH, et al.The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population.J Thorac Oncol. 2025;20(2):167-176.
[15] 李沛闻. 奥希替尼的潜在致心脏毒性作用及机制研究[D].河南大学,2023.
[16] 汪龙,张莉,朱玲娜,等.奥希替尼相关心脏毒性的研究进展[J].中国医院药学杂志,2023,43(13):1516-1520.
[17] Zhang Q, Liu H, Yang J. Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review. Front Endocrinol (Lausanne). 2022 May 23;13:833929.
[18] Sonehara K, Tateishi K, Yoh K, et al.Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study. Thorac Cancer. 2025;16(2):e15507. |
